Skip to content

SANGUI BIOTECH INTERNATIONAL INC: 10-Q filed 2020-11-13

What SANGUI BIOTECH INTERNATIONAL INC reported in its quarterly report filed 2020-11-13 (fiscal Q1 2021): 28 published measures, 59 facts as tagged in accession 0001551163-20-000092.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-13
Fiscal period
fiscal Q1 2021
Accession
0001551163-20-000092 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SANGUI BIOTECH INTERNATIONAL INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-30148,771USD
At 2020-06-30125,328USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-30955,071USD
At 2020-06-30855,206USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-158,222USD
At 2020-06-30-82,901USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-3021,125USD
At 2020-06-3015,282USD
At 2019-09-3020,585USD
At 2019-06-3027,453USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-74,888USD92
2019-07-01 to 2019-09-30-42,749USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-29,519USD92
2019-07-01 to 2019-09-30-31,258USD92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-07-01 to 2020-09-3019,880USD92
2019-07-01 to 2019-09-30282USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-07-01 to 2020-09-3035,305USD92
2019-07-01 to 2019-09-3022,130USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-37,771,313USD
At 2020-06-30-37,696,425USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2019-07-01 to 2019-09-300USD92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-301,802USD
At 2020-06-301,922USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-44,410USD92
2019-07-01 to 2019-09-30-55,898USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3065,980USD
At 2020-06-3048,696USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-07-01 to 2020-09-304,198USD92
2019-07-01 to 2019-09-303,213USD92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-30891,708USD
At 2020-06-30791,485USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-09-3023,602USD
At 2020-06-309,858USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-3064,290USD92
2019-07-01 to 2019-09-3056,180USD92

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-3019,880USD92
2019-07-01 to 2019-09-30282USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-302,427USD92
2019-07-01 to 2019-09-302,236USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-30203,301,842shares
At 2020-06-30203,301,842shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-304,513,328USD
At 2020-06-304,513,328USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-09-3091,474USD
At 2020-06-3091,907USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2020-09-30-806,300USD
At 2020-06-30-729,878USD
At 2019-09-30-588,212USD
At 2019-06-30-591,989USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-09-3081,494USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-75,989USD92
2019-07-01 to 2019-09-30-44,005USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-3011,749USD92
2019-07-01 to 2019-09-3012,192USD92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-31,579USD92
2019-07-01 to 2019-09-3011,893USD92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-3013,778USD92
2019-07-01 to 2019-09-30-28,055USD92

Inspect the source

Entity
SANGUI BIOTECH INTERNATIONAL INC / CIK 0001104280
Captured
SEC response SHA-256
80929a3d07bdd3be99cfb5858d464edb9844d0e622d958ee5dce9515baeeed6f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001104280.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))